+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Blepharitis - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • March 2021
  • Region: Global
  • DelveInsight
  • ID: 4036862
UP TO OFF until Dec 31st 2023
This “Blepharitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Blepharitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Blepharitis Understanding

Blepharitis: Overview

Blepharitis is a common eye condition that makes your eyelids red, swollen, irritated, and itchy. It can cause crusty dandruff-like flakes on your eyelashes. Blepharitis can be uncomfortable. But it isn't contagious, and it usually doesn't cause any lasting damage to your eyes. The main treatment for blepharitis is regularly cleaning your eyelids and keeping them free of crusts. Blepharitis usually doesn't go away completely, but you can take steps to manage your symptoms. Talk to your eye doctor about what's causing your blepharitis and the best ways to manage it.

"Blepharitis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blepharitis pipeline landscape is provided which includes the disease overview and Blepharitis treatment guidelines. The assessment part of the report embraces, in depth Blepharitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blepharitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Blepharitis R&D. The therapies under development are focused on novel approaches to treat/improve Blepharitis.

Blepharitis Emerging Drugs Chapters

This segment of the Blepharitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Blepharitis Emerging Drugs

NCX 4251: NicOx

4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals which is being developed as the first targeted topical treatment of the eyelid margin for patients with acute exacerbations of blepharitis. The drug is in phase 2 of clinical trials for the treatment of blepharitis.

TP-03: Tarsus Pharmaceuticals,

TP-03 (lotilaner ophthalmic solution 0.25%) is a novel therapeutic designed to target and eradicate Demodex mites. It is a potent, non-competitive antagonist of insect and arachnid GABA-Cl channels and a highly lipophilic molecule, which may promote its uptake in the oily sebum of the hair follicle where the mites reside. The company has recently initiated a phase 3 trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis.

Blepharitis: Therapeutic Assessment

This segment of the report provides insights about the different Blepharitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Blepharitis

There are approx. 4+ key companies which are developing the therapies for Blepharitis. The companies which have their Blepharitis drug candidates in the most advanced stage, i.e. phase II include, NicOx.


This report covers around 4+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Blepharitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Blepharitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blepharitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blepharitis drugs.

Blepharitis Report Insights

  • Blepharitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Blepharitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Blepharitis drugs?
  • How many Blepharitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blepharitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Blepharitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Blepharitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • NicOx
  • Tarsus Pharmaceuticals
  • AxeroVision
  • InSite Vision

Key Products

  • NCX 4251
  • TP-03
  • AXR-270
  • ISV-305

Table of Contents


Executive Summary

Blepharitis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Blepharitis - Analytical Perspective

In-depth Commercial Assessment
  • Blepharitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Blepharitis Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

TP-03: Tarsus Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

NCX 4251: NicOx
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Blepharitis Key Companies

Blepharitis Key Products

Blepharitis- Unmet Needs

Blepharitis- Market Drivers and Barriers

Blepharitis- Future Perspectives and Conclusion

Blepharitis Analyst Views

Blepharitis Key Companies

AppendixList of Tables
Table 1 Total Products for Blepharitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Blepharitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • NicOx
  • Tarsus Pharmaceuticals
  • AxeroVision
  • InSite Vision